Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) introduced a new platinum resistance AI signature to its Caris AI Insights portfolio on March 16, 2026. The model predicts early platinum resistance in high-grade serous ovarian cancer (HGSOC) using Whole Exome and Whole Transcriptome sequencing plus clinical data, providing a risk score, platinum sensitive/platinum resistant prediction and supporting Kaplan-Meier curves. The insight is available now by request through the Caris Molecular Tumor Board Report when ordering the tissue-based test MI Cancer Seek. Caris previously received FDA approval for MI Cancer Seek in November 2024.
Positive
- Predicts early platinum resistance for HGSOC using multimodal molecular data
- Provides a risk score plus platinum sensitive/platinum resistant predictions and Kaplan-Meier curves
- Available now via the Caris Molecular Tumor Board Report with MI Cancer Seek
- MI Cancer Seek holds FDA approval (November 2024) for simultaneous WES and WTS tissue profiling
- Builds on Caris' multimodal CodeAI platform integrating WES, WTS and clinical real-world data
Negative
- None.
News Market Reaction – CAI
In the Mar 16 session, CAI gained 4.96%, reflecting a moderate positive market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | AI signature launch | Positive | +2.2% | Introduced AI Insights signature guiding first-line PDAC therapy and de-escalation. |
| Feb 24 | AI signature launch | Positive | +3.2% | Added AI-driven breast cancer signature predicting response to capecitabine. |
| Aug 06 | AI study results | Positive | -4.5% | Published AI model study showing improved survival vs PD-L1 testing in breast cancer. |
| Aug 05 | AI study results | Positive | +2.8% | Reported best-in-class AI tissue-of-origin predictions and frequent diagnosis changes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged announcements have generally seen modest positive reactions, with one notable selloff on an otherwise positive AI study.
Over the past year, Caris has repeatedly highlighted its AI capabilities. Breast cancer and tissue-of-origin AI studies in August 2025 showed strong accuracy and survival benefits, while more recent AI Insights signatures for pancreatic and breast cancer, both tied to the MI Cancer Seek platform with FDA approval in Nov 2024, supported treatment selection. Those AI-tagged releases produced mostly positive single-day moves around the 0.92% average, framing today’s ovarian platinum-resistance signature as a continuation of that AI expansion.
Key Terms
high-grade serous ovarian cancer medical
kaplan-meier curves medical
companion diagnostic regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris AI Insights are proprietary and only available to Caris Life Sciences customers
Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets available with its proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.
By harnessing AI across its comprehensive real-world database, Caris is building next-generation multimodal models that accelerate biomarker discovery, enhance therapeutic decision-making and support the development of more personalized cancer treatments.
HGSOC is the most common and aggressive type of ovarian cancer and is often diagnosed at an advanced stage, creating urgency in treatment planning. Platinum resistance, defined as disease progression or recurrence within six months of finishing first-line platinum-based chemotherapy, is estimated to affect 20
The ovarian platinum resistance signature is particularly relevant in light of the recent FDA approval of a combination therapy for patients with platinum-resistant disease. The FDA approved a new combination treatment that opens the door to another option for patients whose cancer has stopped responding to initial platinum-based chemotherapy. The approval underscores the importance of identifying resistance earlier in the treatment course so clinicians can make more informed decisions about subsequent therapy.
"The ability to anticipate which patients are likely to develop early platinum resistance has the potential to significantly improve how we approach ovarian cancer care," said David Spetzler, MS, PhD, MBA, Caris President. "Platinum-based chemotherapy works well for many patients, but when it doesn't, patients need to be able to quickly move on to other therapeutic options."
By identifying complex molecular features associated with platinum resistance, this signature generates a risk score and a "platinum sensitive" or "platinum resistant" prediction that estimates the likelihood of early transition to the next line of treatment using features from the Caris industry-leading Whole Exome and Whole Transcriptome tissue platform. Also, clinicians receive supporting Kaplan-Meier curves to help contextualize the risk and assist with treatment planning. The Caris AI Insights for ovarian cancer is available now, by request, through the Caris Molecular Tumor Board Report when ordering Caris' tissue-based test, MI Cancer Seek®.
Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-introduces-powerful-new-caris-ai-insights-to-identify-early-platinum-resistance-in-ovarian-cancer-302714113.html
SOURCE Caris Life Sciences